Business
Issue of shares to non-executive directors
Issue of shares to non-executive directors.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n7 May 2025\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nIssue of shares to non-executive directors\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the issue of new ordinary shares of 4p each in the capital of the Company (\"Ordinary Shares\") to certain non-executive directors of the Company in satisfaction of part of their salary and fees for the six-month period ended 31 March 2025.\n \nAs disclosed in the Company's annual report and accounts for the year ended 31 March 2024 (as announced on 5 September 2024), the Company's non-executive directors agreed to receive part of their salary in new Ordinary Shares until the end of the financial year ending 31 March 2025 (\"FY25\"), in order to assist the Company as it continues to carefully control its cash flows.\n \nIn total, 338,113 new Ordinary Shares have been issued (the \"Director Shares\") at a deemed issue price of 6.1p per Ordinary Share, being the closing mid-market price of an Ordinary Share on the date of grant, as follows:\n \n\n\n\n\nDirector\n\n\nAmount of salary/fees received in Director Shares\n\n\nNo. of Director Shares\n\n\nTotal holding of Ordinary Shares post issue\n\n\nPercentage of enlarged share capital\n\n\n\n\nSimon Douglas\n\n\n£3,750\n\n\n61,475\n\n\n1,061,0621\n\n\n0.93%\n\n\n\n\nColin Walsh2\n\n\n£13,500\n\n\n221,311\n\n\n3,109,1123\n\n\n2.74%\n\n\n\n\nMatthew Baker\n\n\n£3,375\n\n\n55,327\n\n\n292,902\n\n\n0.26%\n\n\n\n\n \n1 Excludes Ordinary Shares held by relatives of Simon Douglas.\n2 Held by Walsh Strategic Management Limited, a company controlled by Colin Walsh\n3 Includes 600,000 Ordinary Shares already held by Walsh Strategic Management Limited, a company controlled by Colin Walsh and 1,400,000 Ordinary Shares held by Hamniv (GP) Limited, a subsidiary of Crescent Capital NI Limited (\"Crescent Capital\"). Colin ...